Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Jeppe Zacho"'
Autor:
Børge G Nordestgaard, Tom M Palmer, Marianne Benn, Jeppe Zacho, Anne Tybjaerg-Hansen, George Davey Smith, Nicholas J Timpson
Publikováno v:
PLoS Medicine, Vol 9, Iss 5, p e1001212 (2012)
BackgroundAdiposity, assessed as elevated body mass index (BMI), is associated with increased risk of ischemic heart disease (IHD); however, whether this is causal is unknown. We tested the hypothesis that positive observational associations between
Externí odkaz:
https://doaj.org/article/979c92f2ac1d4f96a089edcea3a8a962
Autor:
Vanita R. Aroda, Srikanth Bellary, Gurudutt Nayak, Yutaka Seino, Jeppe Zacho, L.H. Damgaard, Robert Silver, Helena W. Rodbard, Irene Hramiak
Publikováno v:
Endocrine Practice. 25:589-597
Objective: Semaglutide is a glucagon-like peptide 1 (GLP-1) analog for the once-weekly treatment of type 2 diabetes (T2D). In the global SUSTAIN clinical trial program, semaglutide demonstrated superior glycated hemoglobin (HbA1c) and body weight red
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0e478f4aa0ac8c4a4e0f090874cea272
https://doi.org/10.4158/ep-2018-0444
https://doi.org/10.4158/ep-2018-0444
Autor:
Vanita R. Aroda, Morten Donsmark, Trine Saugstrup, Jeppe Zacho, John B. Buse, Melanie J. Davies
Publikováno v:
Diabetes, Obesity & Metabolism
Regulatory guidelines describe the use of estimands in designing and conducting clinical trials. Estimands ensure alignment of the objectives with the design, conduct and analysis of a trial. An estimand is defined by four inter‐related attributes:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca4ecef0997d8382b0cd0953f569d9a9
http://europepmc.org/articles/PMC6771751
http://europepmc.org/articles/PMC6771751
Autor:
Ludger Rose, Cyrus Desouza, Thomas R. Pieber, Jeppe Zacho, Thomas Kruse Hansen, Ildiko Lingvay, Katarina Lalic
Publikováno v:
Diabetes Care. 41:1926-1937
OBJECTIVE To investigate the efficacy and safety of once-daily semaglutide in comparison with once-daily liraglutide and placebo in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS This 26-week, multicenter, double-blind trial involved pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7abea7067ce96def980ae4df3bca4ab9
https://doi.org/10.2337/dc17-2381
https://doi.org/10.2337/dc17-2381
Autor:
Vincent Woo, Jeffrey Unger, Srikanth Bellary, O Hansen, Cyrus Desouza, J. Hans DeVries, Jeppe Zacho
Publikováno v:
Diabetes, obesity & metabolism, 20(10), 2426-2434. Wiley-Blackwell
Diabetes, Obesity & Metabolism
Diabetes, Obesity & Metabolism
Aim: To evaluate the potential for semaglutide to help people with type 2 diabetes (T2D) achieve glycated haemoglobin (HbA1c) targets while avoiding unwanted outcomes, such as weight gain, hypoglycaemia and gastrointestinal (GI) side effects. Materia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c33c92c4b330806e038d8b5bd510ace
https://doi.org/10.1111/dom.13396
https://doi.org/10.1111/dom.13396
Publikováno v:
Diabetes, Obesity & Metabolism
Aims To evaluate dose levels for semaglutide, a glucagon-like peptide-1 analogue approved for the treatment of type 2 diabetes, by examining the effects of demographic factors on efficacy and safety in an exposure-response analysis. Methods We analys
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24174363a1445f8fd80a831b61d422b0
https://doi.org/10.1111/dom.13358
https://doi.org/10.1111/dom.13358
Publikováno v:
Diabetes Therapy
Introduction Semaglutide, a new treatment option approved for the treatment of patients with type 2 diabetes mellitus, is a glucagon-like peptide-1 receptor agonist to be injected subcutaneously once weekly. This analysis used a population pharmacoki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62ce1082a17d9bd5c6b9907d81d2ad31
https://doi.org/10.1007/s13300-018-0458-5
https://doi.org/10.1007/s13300-018-0458-5
Autor:
Yuichiro Yamada, Tomoyuki Nishida, Hirotaka Watada, Atsuko Abiko, Arihiro Kiyosue, Jeppe Zacho, Kohei Kaku
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To evaluate the safety and efficacy of once‐weekly subcutaneous semaglutide as monotherapy or combined with an oral antidiabetic drug (OAD) vs an additional OAD added to background therapy in Japanese people with type 2 diabetes (T2D) inadequat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::238583e5653864c02686288bfa69c499
https://doi.org/10.1111/dom.13218
https://doi.org/10.1111/dom.13218
